Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiwan Biomaterial Co., Ltd. (6649:TWSE), powered by AI.
Taiwan Biomaterial Co., Ltd. is currently trading at $37.45. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Taiwan Biomaterial Co., Ltd. on Alpha Lenz.
View Taiwan Biomaterial Co., Ltd.'s valuation metrics on Alpha Lenz.
“Taiwan Biomaterial Co., Ltd.'s ROE is 9.0%. Explore profitability and growth together.”
Ask for details →Taiwan Biomaterial Co., Ltd. is a developer and manufacturer of advanced implantable medical equipment, operating within the healthcare supplies sector. The company specializes in the research, development, and production of high-end implantable devices, including biomaterials such as foam-based medical components, specialized interventional devices for stroke treatment, and regenerative products for early degenerative arthritis. Taiwan Biomaterial’s core strength lies in its close collaboration with clinicians to identify unmet medical needs encountered in surgical practice, which then guides its innovation pipeline from concept through clinical validation to commercial rollout. By leveraging a multidisciplinary technological base and robust regulatory compliance, the company brings novel products to global markets, partnering with international brands for distribution or licensing to maximize the value of its proprietary technologies. Taiwan Biomaterial Co., Ltd. plays a significant role in advancing biomaterials and interventional therapies, contributing to the broader medical device industry with a focus on clinical efficacy and market impact.
“Taiwan Biomaterial Co., Ltd.'s ROE is 9.0%. Explore profitability and growth together.”
Ask for details →Taiwan Biomaterial Co., Ltd. (ticker: 6649) is a company listed on TWSE in the Healthcare sector (Medical Devices). It has approximately 35 employees.
The current price is 37.45 with a P/E ratio of -x and P/B of -x.
ROE is 8.99% and operating margin is 27.60%. Annual revenue is $220M.